Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Stryker Corporation's third-quarter 2025 earnings results illustrate a landscape of both opportunity and challenge for the company and its investors.</li><li>The company reported a robust organic sales growth of 9.5%, with standout performances in its Orthopaedics division, which saw double-digit growth.</li><li>This is a testament to the company's strong market demand across its various business sectors, including MedSurg and Neurotechnology.</li></ul>

Stryker Corporation's third-quarter 2025 earnings results illustrate a landscape of both opportunity and challenge for the company and its investors.The company reported a robust organic sales growth of 9.5%, with standout performances in its Orthopaedics division, which saw double-digit growth.This is a testament to the company's strong market demand across its various business sectors, including MedSurg and Neurotechnology.

Stryker Corporation Unleashes Mako—Will Robotics Dominate the OR?

<ul><li>Stryker Corporation's second quarter of 2025 results underscore the company's strong standing amidst varying market conditions.</li><li>The company achieved double-digit organic sales growth of 10.2% alongside a 11.4% growth in adjusted earnings per share (EPS), which is commendable given the challenges like tariffs, non-recurring engineering (NRE) dilution, and strategic divestitures in the spinal implants sector.</li><li>Positive trends were observed across Stryker's diverse product portfolio.</li></ul>

Stryker Corporation's second quarter of 2025 results underscore the company's strong standing amidst varying market conditions.The company achieved double-digit organic sales growth of 10.2% alongside a 11.4% growth in adjusted earnings per share (EPS), which is commendable given the challenges like tariffs, non-recurring engineering (NRE) dilution, and strategic divestitures in the spinal implants sector.Positive trends were observed across Stryker's diverse product portfolio.

Stryker Corporation: Strategic Acquisitions & Organic Launches to Adapt To Changing Market Demands & Needs!

<ul><li>Stryker Corporation reported a strong first quarter, reflecting continued robust demand and effective commercial execution across its diverse product portfolio.</li><li>The company's financial outcomes underscore balanced growth and strategic maneuvering, driven by both organic growth and strategic acquisitions.</li><li>Stryker demonstrated vigorous organic sales growth at 10.1% year-over-year, notably achieving double-digit growth in its MedSurg and Neurotechnology divisions.</li></ul>

Stryker Corporation reported a strong first quarter, reflecting continued robust demand and effective commercial execution across its diverse product portfolio.The company's financial outcomes underscore balanced growth and strategic maneuvering, driven by both organic growth and strategic acquisitions.Stryker demonstrated vigorous organic sales growth at 10.1% year-over-year, notably achieving double-digit growth in its MedSurg and Neurotechnology divisions.

Stryker Corporation: Is Its Tuck-in Acquisition Strategy to Ensure Market Leadership In The Med-Tech Landscape?

<ul><li>Stryker Corporation reported strong financial performance in its fourth quarter of 2024 and the full fiscal year, demonstrating resilience and robust growth across its business segments.</li><li>The company's organic sales growth exceeded 10% for both periods, with U.S. sales growth at 10.6% and international sales at 8.8%.</li><li>Key drivers included double-digit growth in the Instruments, Endoscopy, Medical, Neuro Cranial, and Trauma and Extremities businesses.</li></ul>

Stryker Corporation reported strong financial performance in its fourth quarter of 2024 and the full fiscal year, demonstrating resilience and robust growth across its business segments.The company's organic sales growth exceeded 10% for both periods, with U.S. sales growth at 10.6% and international sales at 8.8%.Key drivers included double-digit growth in the Instruments, Endoscopy, Medical, Neuro Cranial, and Trauma and Extremities businesses.

Stryker Corporation: Leveraging Mako Robotic-Assisted Surgeries To Redefine the Industry! - Major Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic Plc (MDT US)</a> reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.</li>
<li>The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.</li>
<li>In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.</li>
</ul>



Medtronic Plc (MDT US) reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.
The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.
In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.


Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

United States

Stryker Corporation develops, manufactures, and markets specialty surgical and medical products.  The Company's products include implants, biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Stryker Corp (SYK US)

Stryker Corporation Unleashes Mako—Will Robotics Dominate the OR?

Stryker Corporation's third-quarter 2025 earnings results illustrate a landscape of both opportunity and challenge for the company and its...

Baptista Research

Stryker Corporation: Strategic Acquisitions & Organic Launches to Adapt To Changing Market Demands & Needs!

Stryker Corporation's second quarter of 2025 results underscore the company's strong standing amidst varying market conditions. The company...

Baptista Research

Stryker Corporation: Is Its Tuck-in Acquisition Strategy to Ensure Market Leadership In The Med-Tech Landscape?

Stryker Corporation reported a strong first quarter, reflecting continued robust demand and effective commercial execution across its diverse...

Baptista Research

Stryker Corporation: Leveraging Mako Robotic-Assisted Surgeries To Redefine the Industry! - Major Drivers

Stryker Corporation reported strong financial performance in its fourth quarter of 2024 and the full fiscal year, demonstrating resilience and...

Baptista Research

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Stryker Corporation Unleashes Mako—Will Robotics Dominate the OR?

Stryker Corporation's third-quarter 2025 earnings results illustrate a landscape of both opportunity and challenge for the company and its...

Baptista Research

Stryker Corporation: Strategic Acquisitions & Organic Launches to Adapt To Changing Market Demands & Needs!

Stryker Corporation's second quarter of 2025 results underscore the company's strong standing amidst varying market conditions. The company...

Baptista Research

Stryker Corporation: Is Its Tuck-in Acquisition Strategy to Ensure Market Leadership In The Med-Tech Landscape?

Stryker Corporation reported a strong first quarter, reflecting continued robust demand and effective commercial execution across its diverse...

Baptista Research

Stryker Corporation: Leveraging Mako Robotic-Assisted Surgeries To Redefine the Industry! - Major Drivers

Stryker Corporation reported strong financial performance in its fourth quarter of 2024 and the full fiscal year, demonstrating resilience and...

Baptista Research

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

​Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...